Payment overview · 2025
General Payments
$106.01
5 reported records · 4 companies
Healthcare provider profile · identity verified
Jonathan A. Arbogast, MD
Allopathic & Osteopathic Physicians|Family Medicine · CLIO, MI · NPI 1326140906
Verified facts
What the public records show
CMS Open Payments records show Jonathan A. Arbogast, MD received $106.01 in general payments during 2025 across 5 reported records.
Vanda Pharmaceuticals Inc. accounted for 42.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.03 | 42.5% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $21.61 | 20.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.38 | 20.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.99 | 17.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $106.01 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $45.03 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 692 | 184 |
| Lisinopril | Lisinopril | 498 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 494 | 126 |
| Omeprazole | Omeprazole | 387 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 364 | 77 |
| Simvastatin | Simvastatin | 351 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 91 |
| Losartan Potassium | Losartan Potassium | 306 | 87 |
| Metformin Hcl | Metformin Hcl | 283 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 60 |
| Gabapentin | Gabapentin | 178 | 56 |
| Prednisone | Prednisone | 170 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 44 |
| Alprazolam | Alprazolam | 152 | 46 |
| Eliquis | Apixaban | 152 | 36 |
| Montelukast Sodium | Montelukast Sodium | 132 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 125 | 32 |
| Tramadol Hcl | Tramadol Hcl | 116 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 44 |
| Bupropion Xl | Bupropion Hcl | 115 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 36 |
| Ibuprofen | Ibuprofen | 113 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 35 |
| Famotidine | Famotidine | 104 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 43 |
| Baclofen | Baclofen | 99 | 47 |
| Furosemide | Furosemide | 99 | 31 |
| Atenolol | Atenolol | 97 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 28 |
| Carvedilol | Carvedilol | 96 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 20 |
| Cephalexin | Cephalexin | 88 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 17 |
| Allopurinol | Allopurinol | 81 | 24 |
| Potassium Chloride | Potassium Chloride | 79 | 25 |
| Trazodone Hcl | Trazodone Hcl | 78 | 22 |
| Methylprednisolone | Methylprednisolone | 75 | 63 |
| Nifedipine Er | Nifedipine | 75 | 21 |
| Glimepiride | Glimepiride | 67 | 19 |
| Trulicity | Dulaglutide | 67 | 17 |
| Finasteride | Finasteride | 66 | 17 |
| Jardiance | Empagliflozin | 66 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 30 |
| Pregabalin | Pregabalin | 61 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 17 |
| Meloxicam | Meloxicam | 60 | 22 |
| Sertraline Hcl | Sertraline Hcl | 60 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 18 |
| Januvia | Sitagliptin Phosphate | 54 | 18 |
| Celecoxib | Celecoxib | 51 | 13 |
| Nystatin | Nystatin | 50 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 49 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 15 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 14 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 12 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 14 |
| Ezetimibe | Ezetimibe | 40 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 37 | 12 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Cilostazol | Cilostazol | 32 | suppressed |
| Diazepam | Diazepam | 32 | 13 |
| Fluconazole | Fluconazole | 32 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | 14 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Levemir Flexpen | Insulin Detemir | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 20 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 18 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Glipizide | Glipizide | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Novolin R | Insulin Regular, Human | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 14 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $106.01 · 5 records | Vanda Pharmaceuticals Inc. | BRIXADI, CAPLYTA, FANAPT, Korlym | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error